Cell Therapy in Dilated Cardiomyopathy: Observational Study
NCT ID: NCT00612911
Last Updated: 2008-02-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
24 participants
OBSERVATIONAL
2005-02-28
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy
NCT00615394
Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy
NCT00629096
Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy
NCT00743639
Autologous Stem Cells in Pediatric Patients With Dilated Cardiomyopathy
NCT01504594
Cell Therapy in Chagas Cardiomyopathy
NCT00349271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Major group
Patients with Idiopathic dilated cardiomyopathy
Cell therapy
bone marrow mononuclear cell
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cell therapy
bone marrow mononuclear cell
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Optimized therapy and for idiopathic dilated cardiomyopathy
* Left ventricular ejection fraction (Simpson) \< 35%
* Peak oxygen consumption (VO2 peak) \< 16 mL.kg-1min-1
* Functional classes II-IV of the NYHA
Exclusion Criteria
* primary valve disease
* excessive use of alcohol or illicit drugs
* pregnancy
* ventricular arrhythmias
* any co-morbidity with impact on survival
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ministry of Health, Brazil
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brazil: National Institute of Cardioloy
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helena F Martino
Role: PRINCIPAL_INVESTIGATOR
Brazil: National Insittute of Cardiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INCL - National Institute of Cardiology Laranjeiras
Rio de Janeiro, Rio de Janeiro, Brazil
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTDil-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.